LifeTec Group - Mitral Valve Meeting 2018, Zürich

We're proud to present...

At the Mitral Valve Meeting in Zürich, from 25 through 27 February 2018, LifeTec Group will provide facilities for the training of clinicians in performing NeoChord’s minimally invasive mitral valve repair procedure.

For LifeTec Group, the Mitral Valve Meeting 2018 will be extra special because the theme of this meeting will be a scientific paper: 

LifeTec Group - Mitral Valve Meeting 2018, Zürich

The Dynamic Cardiac Biosimulator

The Dynamic Cardiac Biosimulator: 

a Method for Training Physicians in Beating-Heart Mitral Valve Repair Procedures

The Journal of Thoracic and Cardiovascular Surgery, Vol. 155, Issue 1, p147–155 [link]

We feel proud because:

LifeTec Group’s Cardiac Biosimulator Platform is ‘wildly popular’ all over the world among scientists, researchers and medical device manufacturers as well as clinicians. The platform, originally used for research purposes, has been used more and more for training purposes too in recent years.

The scientific paper explains the popularity of the Cardiac Biosimulator Platform as a training tool. And let’s not beat about the bush: a publication like that achieves more than any promotional statement could ever do. 

Another reason why we are proud is this:

NCBI calls him 'A living legend in surgery’  (>): professor Walter Randolph Chitwood Jr.

Prof. Chitwood is one of the authors of the published paper, and not only that: he also accepted our invitation to present his personal evaluation of the Cardiac Biosimulator Platform at the 2018 Mitral Valve Meeting in Zürich.

Prof. Chitwood’s presentation is scheduled for Tuesday, February 27, at 10.45 a.m. (link to program)

 

(Incidentally, the 2018 Mitral Valve Meeting in Zürich is organised by yet another big name among surgeons: Prof. Francesco Maisano, MD [link].)

The paper

A quote from The Journal of Thoracic and Cardiovascular Surgery, Vol. 155, Issue 1, p147–155 :

Central message

"A dynamic animal heart biosimulator (ed.: LifeTec Group’s Cardiac Biosimulator Platform) is evaluated during extruded polytetrafluoroethylene artificial chordae implantation into flailing mitral leaflets under echocardiographic navigation. Concomitant hemodynamic changes are displayed simultaneously.

OBJECTIVE:

Previously, cardiac surgeons and cardiologists learned to operate new clinical devices for the first time in the operating room or catheterization laboratory. We describe a biosimulator that recapitulates normal heart valve physiology with associated real-time hemodynamic performance.

Methods

To highlight the advantages of this simulation platform, transventricular extruded polytetrafluoroethylene artificial chordae were attached to repair flail or prolapsing mitral valve leaflets. Guidance for key repair steps was by 2-dimensional / 3-dimensional echocardiography and simultaneous intracardiac videoscopy.

  • LifeTec Group - Cardiac Biosimulator Platform
    LifeTec Group - Cardiac Biosimulator Platform
    LifeTec Group - Cardiac Biosimulator Platform
  • LifeTec Group - Cardiac Biosimulator Platform
    LifeTec Group - Cardiac Biosimulator Platform
    LifeTec Group - Cardiac Biosimulator Platform
  • LifeTec Group - Cardiac Biosimulator Platform
    LifeTec Group - Cardiac Biosimulator Platform
    LifeTec Group - Cardiac Biosimulator Platform
  • LifeTec Group - Cardiac Biosimulator Platform
    LifeTec Group - Cardiac Biosimulator Platform
    LifeTec Group - Cardiac Biosimulator Platform
  • LifeTec Group - Cardiac Biosimulator Platform
    LifeTec Group - Cardiac Biosimulator Platform
    LifeTec Group - Cardiac Biosimulator Platform
  • LifeTec Group - Cardiac Biosimulator Platform
    LifeTec Group - Cardiac Biosimulator Platform
    LifeTec Group - Cardiac Biosimulator Platform

Results

Multiple surgeons have assessed the use of this biosimulator during artificial chordae implantations. This simulation platform recapitulates normal and pathologic mitral valve function with associated hemodynamic changes. Clinical situations were replicated in the simulator and echocardiography was used for navigation, followed by videoscopic confirmation.

Conclusions

This beating heart biosimulator (ed.: LifeTec Group’s Cardiac Biosimulator Platform) reproduces prolapsing mitral leaflet pathology. It may be the ideal platform for surgeon and cardiologist training on many transcatheter and beating heart procedures."

< Unquote >

testimonial

Dr. Michael A. Borger, Columbia NewYork-Presbytarian, just experienced working with NeoChord's mitral valve repair device and the LifeTec Group Cardiac Biosimulator platform...

Develop skills, reduce risks, minimally invasive, and animal-friendly too

Many surgeons and cardiologists dedicate their lives to the welfare of their patients. They spend their entire careers developing their skills all the time. LifeTec Group’s Cardiac Biosimulator Platform supports them in that.

The better their skills, the lower the risks. This benefits patients, hospitals, health insurers and ‘the cost of care’ in general. 

Minimally Invasive is a relatively new development in which biomedical technology plays an important part. Minimally invasive procedures are easier on the patients as they need less time to recuperate and will be up and about sooner. This is good for patients and their families first and foremost, but it’s also pleasant for employers (less sick leave), for insurers (lower costs) and for hospitals (more beds available means shorter waiting lists). 

Another issue that receives more and more attention, we’re happy to report, is the use of lab animals. The fewer animals are used the better, in our opinion. All the research platforms LifeTec Group develops, as well as all our in-house R&D work and all the trainings we provide in Eindhoven and across the globe all have one important thing in common: no lab animals are used!

So that also goes for:

"The Dynamic Cardiac Biosimulator"

The authors of this paper are:

Alberto M. Leopaldi, PhD, Krzysztof Wrobel, MD, Giovanni Speziali, MD, Sjoerd van Tuijl, BSc (LifeTec Group), Agne Drasutiene, MD, W. Randolph Chitwood Jr., MD

Schedule a meeting in Zürich?

Jurgen de Hart (CEO), Marco Stijnen (Head of Medtech Innovation), Linda Kock (Head of Research), Sjoerd van Tuijl (Senior Research Engineer), Bart Smeets (Research Engineer) and Toine Nagel (Marketing Director) wil attend to the meeting in Zürich.

Please feel free to contact Janneke Cuijpers (Office Manager) if you wish to schedule an appointment:

CEO

Jurgen de Hart

Head of MedTech Innovation

Marco Stijnen

Head of Research

Linda Kock

Office Manager

Janneke Cuijpers

Senior Research Engineer

Sjoerd van Tuijl

Marketing & Communications

Toine Nagel

R&D Engineer

Bart Smeets

©2018 LifeTec Group.  Legal  Credits